January 22, 2021
Torii Pharmaceutical Co., Ltd.
OrphanPacific, Inc.(OrphanPacific) and Torii Pharmaceutical Co., Ltd. (Torii) announced that OrphanPacific has today received manufacturing and marketing approval for ORLADEYO Capsules 150mg (generic name: berotralstat hydrochloride) (hereinafter “ORLADEYO”), a plasma kallikrein inhibitor indicated for the suppression of the onset of attacks in acute hereditary angioedema (HAE) in Japan.
Please visit OrphanPacific’s website for more details of the press release :
English Press Release: OrphanPacific Inc. Receives Manufacturing and Marketing Approval of ORLADEYO Capsules 150mg for Suppression of HAE Attacks in Japan